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Purpose: Ceftazidime/avibactam (CAZ-AVI) is a
fixed-dose combination antibiotic approved in Europe
and the United States for patients with hospital-
acquired pneumonia, including ventilator-associated
pneumonia (HAP/VAP). The economic benefits of a
new drug such as CAZ-AVI are required to be
assessed against those of available comparators, from
the perspective of health care providers and payers,
through cost-effectiveness and cost-utility analyses.
The objective of this analysis was to compare the
cost-effectiveness of CAZ-AVI versus meropenem in
the empirical treatment of appropriate hospitalized
patients with HAP/VAP caused by gram-negative
pathogens, from the perspective of publicly funded
health care in Italy (third-party perspective, based on
the data from the REPROVE (Ceftazidime-Avibactam
Versus Meropenem In Nosocomial Pneumonia,
Including Ventilator-Associated Pneumonia) clinical
study; ClinicalTrials.gov NCT01808092).
Methods: A patient-level, sequential simulation
model of the HAP/VAP clinical course was developed
using spreadsheet software. The analysis focused on
direct medical costs. The time horizon of the model
selected was 5 years, with an annual discount rate of* The datasets used and/or analyzed during the current
study are available from the corresponding author on
reasonable request.
8023% on costs and quality-adjusted life-years (QALYs).
Clinical inputs for treatment comparisons were
mainly obtained from the REPROVE clinical study
data. In addition to clinical outcomes observed in the
trial, the model incorporated impact of resistance
pathogens, based on data from published studies and
expert opinion. Certain assumptions were made for
some model parameters due to a lack of data.
Findings: The analysis demonstrated that the
intervention sequence (CAZ-AVI followed by
colistin + high-dose meropenem) versus the comparator
sequence (meropenem followed by colistin + high-dose
meropenem) provided a better clinical cure rate
(+13.52%), which led to a shorter hospital stay (−0.40
days per patient), and gains in the number of life-years
(+0.195) and QALYs (+0.350) per patient. The
intervention sequence had an estimated net incremental
total cost of V1254 ($1401) per patient, and the
estimated incremental cost-effectiveness ratio was V3581
($4000) per QALY gained, well below the willingness-to-
pay threshold ofV30,000 ($33,507) perQALY in Italy.
Implications: The model results showed that CAZ-
AVI is expected to provide clinical benefits inhttps://doi.org/10.1016/j.clinthera.2020.03.014
0149-2918/$ - see front matter
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E. Tichy et al.hospitalized patients with HAP/VAP in Italy at an
acceptable cost compared to meropenem. (Clin Ther.
2020;42:802e817) © 2020 The Authors. Published by
Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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lator-associated pneumonia.INTRODUCTION
Hospital-acquired pneumonia (HAP) is a nosocomial
pulmonary infection that occurs in patients after >2
days of hospitalization, irrespective of their stay in
the intensive care unit (ICU) or general ward.1,2
Ventilator-associated pneumonia (VAP) occurs after
2e3 days of tracheal intubation and mechanical
ventilation in hospitalized patients in the ICU.1e3 The
incidence of HAP ranges from 5 to >20 cases per
1000 admissions, while the incidence of VAP ranges
from 2 to 16 cases per 1000 ventilation days.1,4
HAP/VAP is associated with considerable mortality,
with the greatest risk in the elderly, along with an
increased burden on health care systems. Economic
burden associated with HAP/VAP is high. In the
United States, mean hospitalization costs were
~$100,000 and $60,000 for a single episode of HAP
with and without VAP, respectively (costing year
2008 and 2009).5 In a UK study, a conservative
estimate of the additional cost of treating HAP with
VAP was ~₤10,000 ($13,127) (costing year 2008 and
2009) compared to HAP without VAP; while in a
Turkish publication, the costs of HAP per episode
were $2832 with and $869 without VAP (costing
year 2000e2002).6
The common pathogens associated with HAP/VAP
differ per an ICU patient's characteristics, length of
hospital stay and ICU stay, and local risk factors.
Staphylococcus aureus (including methicillin-resistant
S aureus [MRSA]), Pseudomonas aeruginosa,
Acinetobacter baumannii, and Enterobacteriaceae
(such as Klebsiella spp, Enterobacter spp) are the
major bacterial strains that cause HAP/VAP.2,7e9
Treatment guidelines for HAP recommend empirical
treatment with combinations of antibiotics based on
patient-specific considerations and local risk factors,
such as the resistance pattern within a specificMay 2020hospital, until the results of microbiological testing
are available after 2e3 days.2,7 However, there is
increased resistance to existing antibiotics, due to the
evolution of multidrug-resistant pathogens in HAP/
VAP causing the failure of initial empirical therapy in
20%e40% of patients with HAP.2 Increased
antibiotic resistance has resulted in a significant
unmet need for antibiotics that are effective against
these resistant pathogens and that can reduce lengths
of hospital stays, costs, and resource utilization.7
Ceftazidime/avibactam (CAZ-AVI) is a fixed-dose
combination antibiotic, containing a third-generation
cephalosporin ceftazidime and a noneb-lactam, b-
lactamase inhibitor avibactam, that has been
approved in the European Union and the United
States for patients with HAP/VAP. This approval was
based on the results of a Phase III, multicenter,
randomized, double-blind, parallel-group,
noninferiority study in patients with HAP, including
VAP (the REPROVE study [Ceftazidime-Avibactam
Versus Meropenem In Nosocomial Pneumonia,
Including Ventilator-Associated Pneumonia];
ClinicalTrials.gov NCT01808092). The study results
demonstrated the noninferiority of CAZ-AVI to
meropenem in clinical cure rates at the test-of-cure
(TOC) visit and supported the role of CAZ-AVI in
treating serious gram-negative infections as a
carbapenem-sparing strategy with no new safety
concerns.10
The incidence of infection with gram-negative
pathogens is high in Italy. In ~25%e50% of cases
are the result of Klebsiella pneumoniae isolates
resistant to carbapenems, in 25%e50% of the cases
are P aeruginosa isolates resistant to carbapenems,
and 10%e50% of strains are classified as multidrug
resistant; furthermore, in up to 50% of cases
Acinetobacter baumannii have combined resistance to
fluoroquinolones, aminoglycosides, and
carbapenems.11 In Italy, the consumption of
antibiotics out-of-hospital is high, ranking fifth in
Europe, with 27.8 doses per 1000 inhabitants.12
Per economic evaluation guidelines in Italy, the
economic benefits of a new drug are required to be
assessed from the perspective of health care providers
and payers through cost-effectiveness and cost-utility
analyses, comparing the new drug to available first-
and second-line treatments.13 Similar to other clinical
trials of antibiotics, the REPROVE study was
conducted with a noninferiority design due to ethical803
Clinical Therapeuticsreasons and thus was not designed to show superiority
of CAZ-AVI versus the comparator. In addition, most
clinical trials do not include patients with suspected
resistance to the study drugs, which limits the
interpretation of the true economic value of a new
antibiotic, such as CAZ-AVI, which could be an
alternate treatment option against resistant
pathogens, given the rise of antimicrobial resistance
in clinical practice. Health economic evaluation
assists in understanding the balance between the
incremental health and economic outcomes provided
by CAZ-AVI versus incremental drug cost. The
objective of this study was to compare the cost-
effectiveness of CAZ-AVI versus meropenem in the
empirical treatment of appropriate hospitalized
patients with HAP/VAP from the publicly funded
(third-party payer) perspective in Italy.MATERIALS AND METHODS
No human subjects were enrolled in this study;
therefore, the study was exempted from regulations
guiding the protection of human subjects.
Model Overview and Structure
A patient-level, sequential simulation model of the
clinical course of HAP/VAP following the initiationFigure 1. Model structure. CAZ-AVI ¼ ceftazidime/avi
including ventilator-associated pneumonia; EO
804of anti-infective empirical treatment (ie, CAZ-AVI or
meropenem) was developed using Excel 2016
software (Microsoft Corporation, Redmond,
Washington). Each patient's pathway is described in
the model structure depicted in Figs. 1 and 2. Patient-
level simulation allowed the management of patient
characteristics, particularly treatment switching, to be
simulated at detailed levels, as opposed to Markov-
type models, which require many simplifying
assumptions.
At the beginning of the model, 5000 patients with
HAP/VAP were created, and Monte Carlo sampling
was used to assign clinical characteristics based on
pathogen type, including resistant pathogens. In the
next step, 2 identical cohorts were generated by
duplicating simulated patients, with 1 cohort
receiving CAZ-AVI and the other receiving
meropenem as an empirical treatment, which
ensured that factors other than treatment did not
affect the comparisons. Patients were then assigned
times for all possible events by sampling whether or
not the event occurred, based on the probability of
the event (eg, probability of adverse event [AE] or
death) and if the event occurred, the time of the
event was assigned based on uniform distribution of
the time window of the particular event (eg, duringbactam; HAP/VAP ¼ hospital-acquired pneumonia
T ¼ end of treatment; TOC ¼ test-of-cure.
Volume 42 Number 5
Figure 2. Overview of the patient flow. AE ¼ adverse event; EOT ¼ end-of-treatment visit; TOC ¼ test-of-cure
visit (21e25 days following the initiation of treatment).
E. Tichy et al.treatment duration for AE, during time in hospital for
in-hospital death). As these events were expected to
occur randomly over a short time period, equal
probability during the time window was assumed.
For some events, the times assigned were based on
the treatments received (eg, time to AE, time to end
of treatment [EOT]).
Each patient who entered the model received
empirical treatment with either CAZ-AVI or
meropenem. Patients continued the empirical
treatment until microbiological test results were
available (at 48e72 h). If microbiological results
revealed that at least 1 of the pathogens was resistant
to the empirical treatment, the patient was switched
to the next treatment and was counted as a clinicalMay 2020failure. The empirical treatment was continued if no
resistance was observed.
At the EOT, each patient's response was assessed. In
cases of response, the patients continued to follow-up
and were assigned a time to first follow-up visit,
which was equivalent to the TOC visit in the clinical
trial (21e25 days post-initiation of treatment). In
cases of nonachievement of response, patients were
considered as treatment failures and were switched to
the next treatment.
At the first follow-up visit (TOC visit), achievement
of clinical cure was assessed in patients. If clinical cure
was again not achieved, the patient was switched to the
next line of treatment. Patients were also exposed to
risk for in-hospital death due to HAP/VAP. In cases805
Clinical Therapeuticsof AE, the medical cost of managing the AE was
accrued and patients may have been switched to the
next treatment line. In cases of death, the drug and
hospitalization costs were accrued along with life-
years (LYs) and quality-adjusted (QA) LYs, and these
patients were exited from the model.
To take into account the additional burden of
resistant pathogens in empirical treatment, the base-
case analysis assumed that in these cases response/
cure rates in subsequent treatment would be reduced
by 10%; this percentage was based on experts'
opinion (A.T. and M.B.). In addition, 10% higher
hospital daily costs were accrued for the increased
health care resource utilization to treat patients with
antibiotic resistance (eg, additional nursing care,
diagnostic testing, and use of isolation rooms).14
Patients with pathogens resistant to empirical
treatment were also assigned a 20% increase in
mortality compared to patients who did not have
resistance but did receive inappropriate
treatment.14e16 These numbers were tested in
scenario analyses.Treatment Comparison
The base-case analysis compared treatment
(intervention and comparator) sequences that
consisted of the empirical treatment followed by a
second-line treatment based on current routine
clinical practice in Italy. The empirical treatments
considered in the model were CAZ-AVI (intervention
sequence) and meropenem (comparator sequence).
The second-line treatment consisted of a combination
of colistin (IV delivery assumed) and high-dose
meropenem for both the intervention and comparator
treatment sequences.
Model Inputs and Data Sources
Baseline and resistant pathogens
The base-case inputs were derived from the top 5
most frequently identified baseline pathogens in the
REPROVE study: K pneumonia (37%), P aeruginosa
(26%), Enterobacter cloacae (14%), Escherichia coli
(12%), and Hemophilus influenzae (9%). The rate of
resistance to CAZ-AVI was based on data from the
published literature, with 7% resistance for P
aeruginosa and 1% each for K pneumonia, E cloacae,
and E coli.17 Rates of resistance to the meropenem
were based on rates of resistance to carbapenems from806the 2017 resistance data observed in patients from
Italy for K pneumonia (52%), P aeruginosa (24%),
and E coli (1%) calculated in a forecast model based
on data from the European Centre for Disease
Prevention and Control18 and the resistance rates were
validated by clinical experts (A.T. and M.B.).
Furthermore, the rate of resistance of K pneumonia to
carbapenems, which had the highest resistance rate
among others, was tested in scenario analysis.
Clinical inputs
Treatment efficacy in the model was characterized
as the response achieved at the EOT visit and clinical
cure achieved at the TOC visit from the REPROVE
clinical trial.10 The model inputs are summarized in
Table I.19e28
In terms of AEs, only serious AEs (SAEs) were
considered due to their relevant cost impact and
because they could result in treatment switches or
discontinuations. The probability of treatment
discontinuation due to AEs (assuming all AEs were
SAEs) was set at 21%, based on REPROVE study data.
Since the REPROVE study showed a low mortality
rate, model inputs for in-hospital deaths from HAP/
VAP were obtained from another published study.4
In-hospital deaths were categorized based on whether
a patient had received appropriate empirical
treatment and whether a patient was infected with a
pathogen(s) resistant to the empirical treatment.
Economic inputs
Model inputs on treatment duration were obtained
from the EU-approved product labels, and it was
assumed that each patient completed the course of
treatment per the label-specified duration, except in
cases of resistance to empirical treatment or an AE
that resulted in treatment discontinuation or the
death of a patient.
The hospitalization costs were calculated as a mean
of the ICU costs and general ward costs, using time
spent in ICU or general ward as weights. Analysis of
data on health care resource utilization from the
REPROVE study provided the inputs for the
percentage of hospitalization days in ICU versus in
general ward and the total length of hospital stay.
These data were further estimated based on whether
a patient was cured at the first follow-up visit.
Model inputs on the costs of SAEs were derived as a
weighted mean cost based on different SAEs reportedVolume 42 Number 5
Table I. Model inputs and data sources.
Inputs Value Source
Clinical cure, %
CAZ-AVI 77.4 REPROVE clinical study data10
Meropenem 78.1
Colistin + high-dose meropenem 58.0 Expert opinion
AE frequencies, %*
CAZ-AVI 8.6 REPROVE clinical study data10
Meropenem 6.5 REPROVE clinical study data10
Colistin + high-dose meropenem 6.5 Assumed to be same as meropenem in
REPROVE study
In-hospital death, %
Appropriate empirical treatment 14.02 Wilke et al (2011)4
Inappropriate empirical therapy 26.36
Resistant to empirical therapyy 31.63
Daily drug costsz (average daily dose)
CAZ-AVI V300 ($335; 7500 mg) Assumption provided by Pfizer
Meropenem V55 ($62; 3000 mg) AIFA19 (except for the cost of colistin,
which was taken from BNF,20 then
converted to Euros using an
exchange rate of £1 ¼ V1.36
[$1.52])
Colistin + high-dose meropenem V120 ($134; 5 mg for
colistin; 6000 mg for
meropenem)
Treatment duration, d
CAZ-AVI 10.5 CAZ-AVI EU label21
Meropenem 12.0 Doripenem EU label, assumed same
as doripenem data given the same
drug class22
Colistin + high-dose meropenem 9.5 Doripenem EU label, assumed same
as doripenem data given the same
drug class22
Hospital cost per day
General ward V309 ($345) Italian hospital diagnosis-related
groups (2013 and 2015)23,24
ICU V1383 ($1545) Tan et al (2012)25
Hospital length of stay, d
With clinical cure 16.4 REPROVE clinical study data10
With clinical failure 19.1 REPROVE clinical study data10
Percentage of hospitalization days in ICU, %
With clinical cure 43.90 REPROVE clinical study data10
With clinical failure 56.02 REPROVE clinical study data10
(continued on next page)




Cost of SAE in the base case
SAE cost V3424 ($3824) Italian hospital diagnosis-related
groups (2013 and 2015)23,24
Utility (quality of life)
With clinical response/cure 0.92 Song et al (2012)26
Without clinical response 0.61 Delate et al (2001)27
Euros converted to USD using an exchange rate of V1 ¼ $1.1169 as of November 1, 2019.28
AE ¼ adverse event; AIFA ¼ Agenzia Italiana del Farmaco, BNF ¼ British National Formulary; CAZ-AVI ¼ ceftazidime-
avibactam; EU ¼ European Union; ICU ¼ intensive care unit; REMOVE ¼ Ceftazidime-Avibactam Versus Meropenem In
Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia.
* AEs considered in the model included only serious AEs, as these have relevant cost impact and can result in treatment
discontinuation or treatment switch.
yMortality of patients with resistant pathogens are assumed to be 20% higher than mortality of patients with inappropriate
empirical therapy without resistance.
zAIFA, Agenzia Italiana del Farmaco, 2014 (except for cost of colistin, which was taken from British National Formulary,
converted to Euros using an exchange rate of £1 ¼ V1.36 [$1.52]).
Clinical Therapeuticsin the REPROVE study. Health utilities, key
components in estimating QALYs, were based on
data obtained from the published literature, as these
were not captured in the REPROVE study, and
published data on utility in nonresponding patients
with HAP/VAP were not identified.
Analyses
The model compared the cost-effectiveness of
empirical treatment with CAZ-AVI (intervention
sequence) versus meropenem (comparator sequence),
followed by second-line treatment of colistin + high-
dose meropenem, from the perspective of publicly
funded health care in Italy, with only direct medical
costs considered. The selected time horizon of the
model in the base-case analysis was 5 years, to cover
the episode of the infection and to evaluate the long-
term impact. An annual discount rate of 3% on costs
and health benefits was applied.13
Cost-effectiveness and cost-utility were analyzed,
and the following health outcomes were evaluated:
percentages of cured patients, LYs gained, and
QALYs gained. These outcomes were combined with
cost data to calculate the incremental cost-
effectiveness ratio (ICER) as the incremental cost per
QALY gained.808The robustness of the results with respect to the
uncertainty in the model input parameters was
evaluated by probabilistic sensitivity analysis (PSA)
using second-order Monte Carlo simulation. Each
parameter (costs and outcomes) was assigned a
probability distribution, and cost-effectiveness results
associated with simultaneously selecting random
values from those distributions were generated.
Health care resource utilization and costs were
assumed to follow a g distribution, while inputs
restricted between 0 and 1 (eg, utilities) were
assumed to follow a b distribution. The SE of the
input parameters was available only for the treatment
duration and for the time of microbiological results.
Assumptions had to be performed at all other inputs
to estimate the SEs, as there was no information on
the variability of these parameters. The variability in
the risks for AEs was assumed to be high; therefore,
the SEs of the AE risks were calculated to be 20% of
the means. For all other inputs, the SEs were
assumed to be 10% of the means. Results of the PSA
were plotted on the cost-effectiveness plane, and cost-
effectiveness acceptability curves were calculated.
One-way deterministic sensitivity analyses were
conducted by varying each parameter as ±20% of the
base-case values while holding all other parametersVolume 42 Number 5
E. Tichy et al.constant to examine the impact of each input
parameter and to define the most influential
parameters. The incremental net benefit (INB) was
defined as the difference between the incremental
QALYs, multiplied by a threshold (willingness to
pay), and the incremental costs were summarized in a
tornado diagram. If the INB was positive, then the
intervention was considered cost-effective; if the INB
was negative, then the intervention was not
considered cost-effective versus the comparator, at
the given threshold.
Scenario analyses were performed, first, as a
conservative case in which the additional burden due
to resistance (ie, reduction in efficacy of second-line
treatment, increase in daily hospital costs, and increase
in mortality) was removed; second, where the rate of
resistance of K pneumonia to carbapenems was
reduced to 30%; and third, where the efficacy of
second-line treatment was set to 100% (ie, assuming
patients were switched to the “correct” treatment in
the second line after the microbiological test results).
RESULTS
Base-Case Results
In the base case (Table II), patients treated with the
intervention sequence had better clinical outcomes
compared to those treated with the comparator
sequence, as a higher proportion of patients had a
clinical cure (+13.52%), which led to a shorter mean
hospital stay (−0.40 days per patient), and gains in
number of LYs (+0.195) and QALYs (+0.350) per
patient. The intervention sequence had an estimated
incremental total cost of V1254 ($1401) per patient
compared to the total costs estimated for the
comparator sequence; this finding was primarily due
to higher costs of drugs (V3067 [$3426] vs V741
[$828]) and AEs (V296 [$331] vs V172 [$192]),
despite lower hospitalization costs (V15,030
[$16,787] vs V16,228 [$18,125]) due to shorter
length of hospital stay. The estimated ICER was
V3581 ($4000) per QALY gained, which was well
below the willingness-to-pay threshold of V30,000
[$33,507] per QALY in Italy (Table II and Fig. 3).
Scenario Results
Ascenario inwhich the additionalburdenof resistance
was removed (ie, the reduced efficacy, increased
probability of death and additional hospital costs) was
tested. In this scenario, the ICER was increased by 63%May 2020(V5851 [$6535] per QALY) compared to the base-case
scenario (V3581 [$4000]). Similarly, in the scenario in
which patients receiving second-line treatment were
assumed to have 100% response/cure rates, the ICER
was increased by 37% (V4922 [$5497] per QALY).
Also, in the scenario in which the rate of resistance of K
pneumonia to carbapenems was decreased from that in
the base case (ie, 30% vs 52%), the ICER was increased
by 145% (V8766 [$9791] per QALY). However, in all
scenarios, the ICERs were <V30,000 (<$33,507) per
QALY, the acceptable willingness-to-pay threshold in
Italy.
Probabilistic Sensitivity Analysis Results
The incremental costs and incremental QALYs of
the intervention versus comparator sequence at the
simulation points calculated in the PSA were plotted
on a cost-effectiveness plane (Fig. 4A). The PSA
results showed that the groupings on the cost-
effectiveness planes had a cluster around the
northeast quadrant, suggesting that the intervention
sequence (ie, CAZ-AVI) was more effective and
costlier than was the comparator sequence (ie,
meropenem) in 52% of the iterations performed in
the PSA. In 30% of the iterations, intervention
sequence (CAZ-AVI) was found to be dominant (ie,
providing better clinical outcomes at lower costs
compared to sequence initiating with meropenem).
The cost-effectiveness acceptability curve (Fig. 4B)
depicted that at a willingness-to-pay threshold of
>V9000 ($10,052) per QALY, the intervention
sequence was an optimal treatment option
representing the maximum net benefit compared to
that of the comparator sequence. Below this
threshold (V9000 [$10,052] per QALY), the
comparator sequence had a higher probability of
being an optimal treatment option.
Deterministic Sensitivity Analysis Results
The tornado graph (Fig. 5) represents the 1-way
deterministic sensitivity analysis results of outcomes
of INB based on a willingness-to-pay threshold of
V30,000 ($33,507) per QALY. The intervention
sequence depicted cost-effectiveness (positive INB of
V9249 [$10,330]) as compared to the comparator
sequence based on the INB from the base case. The
results were based on the top 10 parameters by order
of their influence on the outcomes. The INB was
most influenced by the variation in the response rates809
Table II. Base-case outcomes (discounted by 3%).
Outcomes CAZ-AVI




Followed by Colistin + High-Dose
Meropenem
Clinical outcomes, %
Percentage of patients with cure 72.42 58.90
Percentage of patients who died in hospital 16.32 20.54
Percentage of patients with adverse events 8.66 5.02
Hospital length of stay, mean, d 18.28 18.68
Discounted life-years 3.889 3.694
Discounted QALYs 3.439 3.089
Discounted cost outcomes
Drug costs V3067 ($3426) V741 ($828)
Hospitalization costs V15,030 ($16,787) V16,228 ($18,125)
Adverse event costs V296 ($331) V172 ($192)
Total costs V18,394 ($20,544) V17,140 ($19,144)
ICERs
Incremental cost per QALY gained V3581 ($4000)
CAZ-AVI ¼ ceftazidime-avibactam; ICER ¼ incremental cost effectiveness ratio; QALY ¼ quality-adjusted life-year.
Figure 3. Incremental cost outcomes per patient for ceftazidime/avibactam (CAZ-AVI) sequence versus mer-
openem sequence. Euros converted to USD using an exchange rate of V1 ¼ $1.1169 as of November
1, 2019.28
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Figure 4. Results from probabilistic sensitivity analysis for ceftazidime/avibactam (CAZ-AVI) versus meropenem
in the treatment of hospital-acquired pneumonia including ventilator-associated pneumonia (HAP/
VAP), cost per quality-adjusted life-year (QALY). A, On cost-effectiveness plane B, On cost-
effectiveness acceptability curve. Each dot represents cost-effectiveness outcome from each itera-
tion. The threshold lines represent cost-effectiveness thresholds (V30,000 [$33,507] per QALY); the
maximum amount society is willing to pay for a QALY gain. In cases that fall to the right and below
this line, the intervention (CAZ-AVI) is cost-effective compared to the comparator (meropenem). In
cases that fall to left and above this line, the intervention is not cost-effective compared to the
comparator. Euros converted to USD using an exchange rate of V1 ¼ $1.1169 as of November 1,
2019.28 WTP ¼ willingness to pay.
E. Tichy et al.
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Figure 5. Results from 1-way deterministic sensitivity analyses for ceftazidime/avibactam (CAZ-AVI) versus
meropenem in hospital-acquired pneumonia including ventilator-associated pneumonia (HAP/VAP):
incremental net benefit (INB) based on willingness-to-pay threshold. Positive INB indicates the
intervention (CAZ-AVI) is cost-effective versus the comparator (meropenem), and vice versa. Euros
converted to USD using an exchange rate of V1 ¼ $1.1169 as of November 1, 2019.28 EOT ¼ end of
treatment; Prob ¼ probability; TOC ¼ test-of-cure.
Clinical Therapeuticsat EOT and the cure rates at the TOC assessment for
CAZ-AVI and for meropenem but remained below
the maximum willingness-to-pay threshold in all
instances.
DISCUSSION
The present study is the first economic evaluation of
CAZ-AVI versus meropenem in the empirical
treatment of hospitalized patients with HAP/VAP
from the perspective of publicly funded health care
(third-party payer) in Italy. The base-case analysis
results showed that the intervention sequence (CAZ-
AVI followed by colistin + high-dose meropenem)
versus the comparator sequence (meropenem
followed by colistin + high-dose meropenem) was
associated with an increase in the clinical cure rate,
shorter hospital stays, and higher QALYs at an
acceptable incremental cost of V1254 ($1401) per812patient with HAP/VAP in Italy. The higher drug and
AE costs per patient were offset by reduced
hospitalization costs. Furthermore, CAZ-AVI was
cost-effective compared to meropenem at an ICER
of V3581($4000) per QALY gained, well below the
threshold of V30,000 ($33,507) per QALY in Italy.
The introduction of CAZ-AVI to hospital
formularies in the treatment of HAP/VAP was
expected to have a minimal impact on the health
care budget in Italy, with an estimated increase of
just 0.5% over 3 years.29
The current study was the first to look at the cost-
effectiveness of CAZ-AVI compared to that of
meropenem in the treatment of HAP/VAP, although
other studies of the cost-effectiveness of HAP/VAP
treatments29e33 and of CAZ-AVI have been previously
published.29,34,35 The previously published cost-
effectiveness studies showed CAZ-AVI to be cost-Volume 42 Number 5
E. Tichy et al.effective compared to the comparator (ie, colistin-based
therapy or imipenem) in the treatment of bacteremia,
pneumonia, and complicated urinary tract infection.
In the present study, the model inputs for treatment
comparison were obtained from data from the
REPROVE clinical study, other published studies,
expert opinion, and local databases, with
assumptions being made due to a lack of data on
some model parameters. This approach is consistent
with those from other published studies that have
been compared the cost-effectiveness of antibiotic
treatments of HAP/VAP.29,31,33
In our evaluation, a willingness-to-pay threshold of
V30,000 per QALY was used. A recent publication by
Woods et al (2016)36 suggested an alternate approach
to determine willingness-to-pay threshold in a specific
country in which the relationship between health care
spending and health outcomes is taken into account.
Using the approach suggested, the estimated
threshold calculated for Italy was V15,114 per
QALY (using the following values: gross domestic
product of the United Kingdom ¼ $42,98637; gross
domestic product of Italy ¼ $35,391.7038;
elasticity ¼ 0.736; euros e British ₤ exchange
rate ¼ 1.200939). With the reduced willingness-to-
pay threshold, our cost-effectiveness results including
base case and all scenarios evaluated still remained
below the threshold.
The model analysis had certain limitations. The
REPROVE study was planned as a noninferiority
study and hence lacked the statistical power to show
superiority of CAZ-AVI to meropenem. The
noninferiority study design could have affected the
clinical inputs of the base-case analysis. The model
was thus designed to include the impact of resistant
pathogens, considering the additional economic
burden associated with antibiotic resistance that
cannot be captured in clinical trials (ie, reduction in
cure rates with the second-line treatment, increase in
daily hospitalization costs, and increase in mortality).
In a conservative scenario in which this additional
impact was removed, as expected the ICER was
increased compared to the base case (V5851 [$6535]
vs V3581 [$4000] per QALY); however, it was still
well below the willingness-to-pay threshold of
V30,000 ($33,507) per QALY in Italy.May 2020Furthermore, the model had treatment pathways as
predefined and thus the subsequent treatment choices
cannot be controlled for patients. Hence, in the case of
no microbiological resistance, the model assumed
continuation of empirical treatment with CAZ-AVI or
meropenem and did not allow consideration for de-
escalation of broad-spectrum empirical therapy or dose
adjustment, which could be followed in clinical routine.
Had the model considered de-escalation, that would
have lowered the costs of treatment sequence with
CAZ-AVI, given that more patients responded to the
empirical therapy (mainly due to lower rates of
resistance) and thus lowering the ICER. Therefore, our
analysis can be considered as conservative. In addition,
the clinical inputs for the model were sourced from
REPROVE and other published multicenter,
multinational clinical studies, and it was assumed that
the data were reflective of the population of Italy.
Similarly, the assumption for efficacy of the
combination colistin + high-dose meropenem
specifically in second-line treatment (ie, cure
rate ¼ 58%), was based on expert opinion due to the
unavailability of published evidence. However, one may
argue that, by that time, microbiological test results are
available, so clinicians should be able to switch patients
to the “correct” antibiotic, and thus the success rate
with the second-line treatment should be high. A
scenario analysis that assumed clinical cure rates with
second-line antibiotics would be 100% revealed an
increase in the ICER compared to that in the base case
(V4922 [$5497] vs V3581[$4000] per QALY);
however, it was still well below the willingness-to-pay
threshold of V30,000 [$33,507] per QALY. The model
also did not include the impact of disease transmission
in HAP/VAP. Treating with an appropriate medication
early in an infection can decrease the risk for
transmission. Furthermore, a reduction in the length of
stay in-hospital also decreases this risk. Additionally,
the change in resistance incidence over time was not
considered and was assumed to have been constant. It
was assumed that the distribution of different AEs
observed with other treatments would be similar to that
observed in clinical studies of CAZ-AVI, since AEs were
included as an aggregated AE. Furthermore, the
frequency of AEs with colistin + high-dose meropenem
was considered similar to the frequency of AEs with813
Clinical Therapeuticsmeropenem, although additional AEs, due to the colistin
treatment, were expected. Given that the AE rates for
both treatment sequences and also for the second-line
treatment were very low, these assumptions were not
expected to have had a significant impact on the cost-
effectiveness results. The sensitivity analysis also
revealed AE costs to have had little impact on the ICER
outcome (not even on the top 10 most influential
parameters). Also, the model inputs were based on
Italy-specific data. Therefore, the model results are
applicable to Italy. To calculate the results in other
countries, the model inputs should be replaced by
county-specific inputs. Furthermore, the model
evaluated data from only patients infected with gram-
negative pathogens, which was the target population
for CAZ-AVI treatment. The majority of the HAP/VAP
infections are caused by gram-negative pathogens.40e42
In a European, Serbian study, the percentage of gram-
negative agents in HAP/VAP patients was 95.2%.40
Because the percentage of gram-positive patients among
those with HAP/VAP is small, the inclusion of gram-
positive patients in the analyses would not have
modified the results considerably. Finally, as the
antibiotics are used over time, the resistance rates can
evolve. Therefore, the results of the analysis in the
present study may have to be updated in the long run.
Furthermore, the introduction of CAZ-AVI can
increase diversity in prescribing and provide early
appropriate empirical treatment, with a subsequent
reduction in levels of resistance.43,44
The strengths of the present study ability to included
its capture of the impact of different resistant
pathogens and the evaluation of the whole course
(response, cure, treatment length, hospital discharge,
adverse events) of HAP/VAP experienced by patients.
The efficacy inputs were considered in detail, with
modeling of both cure of patients and probability of
response before the cure, which allowed
nonresponder patients to be switched between
treatments at EOT in the model. Additionally, the
individual patient simulation approach provided a
means to a more realistically modeled treatment
pathway, allowing the effects of treatment switch and
resistance to have been captured in the cost-
effectiveness outcomes despite the noninferiority
nature of the REPROVE study.
One of the challenges with novel antibiotics lies in
getting them into the focus of society, payers, and814decision makers. As this study shows, the introduction
of novel antibiotics such as CAZ-AVI can save lives,
preventing HAP/VAP-related deaths due mainly to
inappropriate empirical treatment, with only minimal
incremental costs. However, novel antibiotics do not
seem to get the attention given to new drugs in other
therapeutic areas, such as oncology, which get media
attention even if they offer relatively little clinical
benefit at high incremental costs.CONCLUSIONS
The choice of an optimal antibiotic in patients with
HAP/VAP should involve careful consideration of
local resistance data, treatment efficacy,
treatmenteresistance profile, and resource burden
associated with management of the infection. The
present study demonstrated that CAZ-AVI, when
compared with meropenem, provided better health
outcomes (ie, clinical cures), shorter times in-hospital,
and thus higher QALYs per patient, at an acceptable
cost. CAZ-AVI was demonstrated as a cost-effective
alternative to meropenem in HAP/VAP in Italy, based
on the willingness-to-pay threshold, resistance levels,
and efficacy data. These findings further support the
use of CAZ-AVI as an alternative treatment in
patients with HAP/VAP.DISCLOSURES
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